Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Aparna Goel, MD
Stanford University
Principal Investigator - Leina Alrabadi, MD
Stanford University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Stanford Clinic
Redwood City, California, United States
Recruiting - Stanford Clinic
Stanford, California, United States
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 10 May 2023
- Primary completion
- 31 May 2027
- Completion
- 31 Dec 2027
- Last update posted
- 13 Jun 2025
- Registered enrollment
- 24
- Registry id
- NCT05295680
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.